Clinical and Molecular Profiling to Develop a Potential Prediction Model for the Response to Alemtuzumab Therapy for Acute Kidney Transplant Rejection

Alemtuzumab, a monoclonal antibody that depletes CD52‐bearing immune cells, is an effective drug for the treatment of severe or glucocorticoid‐resistant acute kidney transplant rejection (AR). Patient‐specific predictions on treatment response are, however, urgently needed, given the severe side eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Hullegie‐Peelen, Daphne M., van der Zwan, Marieke, Clahsen‐van Groningen, Marian C., Mustafa, Dana A.M., Baart, Sara J., Reinders, Marlies E.J., Baan, Carla C., Hesselink, Dennis A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314084/
https://www.ncbi.nlm.nih.gov/pubmed/35202481
http://dx.doi.org/10.1002/cpt.2566

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314084/
https://www.ncbi.nlm.nih.gov/pubmed/35202481
http://dx.doi.org/10.1002/cpt.2566

Ejemplares similares